No, Do Not Increase Chlorthalidone in Suspected Primary Aldosteronism
In a patient with suspected primary aldosteronism (PA), increasing chlorthalidone is inappropriate and potentially harmful—instead, you should initiate mineralocorticoid receptor antagonist (MRA) therapy, specifically spironolactone, as the primary treatment for both blood pressure control and to address the underlying pathophysiology. 1
Why Thiazides Are Problematic in Primary Aldosteronism
Pathophysiologic Mismatch
Primary aldosteronism is driven by autonomous aldosterone excess causing sodium retention, volume expansion, and potassium wasting. Thiazide-type diuretics like chlorthalidone stimulate both renin and aldosterone 2, which can:
- Interfere with diagnostic accuracy of screening tests (aldosterone-to-renin ratio)
- Exacerbate hypokalemia through additive potassium-wasting effects
- Fail to address the root cause of aldosterone-mediated cardiovascular and renal damage
Clinical Evidence of Harm
A 2026 case report dramatically illustrates this risk: a patient with undiagnosed PA on low-dose hydrochlorothiazide (12.5 mg) developed severe hypokalemia (1.6 mmol/L), metabolic alkalosis, and rhabdomyolysis when the dose was increased to just 25 mg 3. This demonstrates that thiazide diuretics can unmask or worsen PA-related complications rather than safely control blood pressure.
The Correct Treatment Approach
First-Line: Mineralocorticoid Receptor Antagonist
Add spironolactone 25-50 mg daily as PA-specific medical therapy 1. The evidence is compelling:
- In resistant hypertension with suspected/confirmed PA, spironolactone reduces office systolic BP by -13.3 mm Hg (95% CI, -17.89 to -8.72) and 24-hour ambulatory systolic BP by -8.46 mm Hg (95% CI, -12.54 to -4.38) 4
- This benefit occurs regardless of whether aldosterone excess is formally documented 5, 6
- Spironolactone is recommended over other MRAs due to low cost and widespread availability 1
Titration Strategy
If blood pressure remains uncontrolled on MRA therapy and renin remains suppressed, increase the MRA dose to raise renin levels 1. Monitor:
- Serum potassium and renal function
- Renin (concentration or activity)
- Blood pressure response
The goal is titrating MRA to achieve a rise in renin from pretreatment baseline, not a specific target number 1.
Diagnostic Considerations Before Treatment Escalation
Complete the PA Workup
Before intensifying any therapy, confirm or exclude PA:
- Screen with aldosterone-to-renin ratio (ARR ≥30, with aldosterone ≥10 ng/dL and suppressed renin <1 ng/mL/h) 2
- Ensure normal serum potassium during testing to avoid false negatives 2
- Withdraw MRAs for ≥4 weeks before screening if possible 2
Risk Stratification
PA carries significantly elevated cardiovascular risk compared to primary hypertension:
- 2.0-fold increased risk of heart failure
- 2.8-fold increased risk of stroke
- 4.0-fold increased risk of atrial fibrillation
- 1.7-fold increased risk of coronary artery disease 2
This excess risk is due to direct toxic tissue effects of aldosterone independent of blood pressure elevation 2, making aldosterone blockade essential rather than simply adding more diuretics.
Common Pitfalls to Avoid
Pitfall #1: Assuming hypokalemia must be present for PA diagnosis. The majority of PA patients are normokalemic 2, so normal potassium does not exclude the diagnosis.
Pitfall #2: Using hydrochlorothiazide instead of chlorthalidone for resistant hypertension generally. While chlorthalidone is superior to hydrochlorothiazide for resistant hypertension 4, 5, neither should be escalated in suspected PA without first addressing aldosterone excess.
Pitfall #3: Failing to monitor for hyperkalemia when adding spironolactone. Risk is increased with:
- Chronic kidney disease (eGFR <45 mL/min/1.73 m²)
- Baseline potassium >4.5 mmol/L
- Diabetes
- Elderly patients
- Concurrent ACE inhibitor or ARB use 1, 6
Pitfall #4: Delaying PA screening. Only 1-2% of appropriate patients are screened despite PA affecting 5-10% of all hypertensive patients and 20% of those with resistant hypertension 2.
Practical Algorithm
- Suspect PA? → Screen with ARR (can be done on most antihypertensives except MRAs)
- ARR positive? → Proceed to confirmatory testing and imaging
- While awaiting workup: Initiate spironolactone 25 mg daily (if K+ ≤4.5 and eGFR ≥45)
- Uncontrolled BP with suppressed renin? → Increase spironolactone to 50 mg daily
- Still uncontrolled? → Add other antihypertensive classes (CCB, ACE-I/ARB), but not more thiazide